Legislating for Good Governance in the Pharmaceutical Sector through UN Convention Against Corruption (UNCAC) Compliance

References

• Anello, E. (2008). A framework for good governance in the public pharmaceutical sector Dr Eloy Anello (WHO consultant). Department of Essential Medicines and Pharmaceutical Policies. http://www.anti-corruption.org/wp-content/uploads/2016/11/WHO-GGMframework.pdf
   Google Scholar
• Baghdadi-Sabeti, G., & Serhan, F. (2010). WHO Good Governance for Medicines programme: An innovative approach to prevent corruption in the pharmaceutical sector. https://moph.gov.lb/userfiles/files/Governance/WHOReport-CountryCaseStudiesandBestPractices.pdf.
   Google Scholar
• Botero-Rodríguez, F., Pantoja-Ruiz, C., & Rosselli, D. (2022). Corruption and its relation to prevalence and death due to noncommunicable diseases and risk factors: A global perspective. Revista Panamericana de Salud Pública, 46, e10. https://doi.org/10.26633/RPSP.2022.10
   PubMedGoogle Scholar
• Bruckner, T. (2019). The Ignored Pandemic. https://ti-health.org/wp-content/uploads/2019/03/IgnoredPandemic-WEB-v3.pdf.
   Google Scholar
• Brunelle-Quraishi, O. (2011). Assessing the relevancy and efficacy of the united nations convention against corruption: A comparative analysis. Notre Dame Journal of International & Comparative Law, 2(1), 101–166. http://scholarship.law.nd.edu/ndjicl/vol2/iss1/3
   Google Scholar
• Conzelmann, T. (2011). Reporting and peer review in the implementation of international rules: What role for Non-state actors? In B. Reinalda (Ed.), The Ashgate research companion to Non-state actors (pp. 319–331). Routledge. https://doi.org/10.4324/9781315613369-28
   Google Scholar
• Country Profiles. (n.d.). UNODC. Retrieved June 5, 2023, from https://www.unodc.org/unodc/en/corruption/country-profile/index.html.
   Google Scholar
• David-Barrett, E., Yakis-Douglas, B., Moss-Cowan, A., & Nguyen, Y. (2017). A bitter pill? Institutional corruption and the challenge of antibribery compliance in the pharmaceutical sector. Journal of Management Inquiry, 26(3), 326–347. https://doi.org/10.1177/1056492617696885
   Web of Science ®Google Scholar
• Economist Intelligence Unit. (2023). Democracy Index 2022. https://www.eiu.com/n/campaigns/democracy-index-2022/.
   Google Scholar
• Forzley, M., Robertson, J., & Smith, A. (2013). Legislation an essential tool for ensuring access to medicines policy goals. WHO South-East Asia Journal of Public Health, 2(1), 69–71. https://apps.who.int/iris/handle/10665/329774
   PubMedGoogle Scholar
• Guterres, A. (2020, October 15). Corruption is the ultimate betrayal of public trust. United Nations; United Nations. https://www.un.org/en/coronavirus/statement-corruption-context-covid-19.
   Google Scholar
• Hechler, H., Fenner, G., Koechlin, Z. L., & Morris, D. (2011). U4 REPORT Can UNCAC address grand corruption? A political economy analysis of the UN Convention against Corruption and its implementation in three countries.
   Google Scholar
• Hussmann, K., & Peñailillo, M. (2007). How can technical assistance support the implementation of UNCAC? https://www.cmi.no/publications/file/3561-how-can-technical-assistance-support-the.pdf.
   Google Scholar
• Karpoff, J. M., Lee, D. S., & Martin, G. S. (2017). Foreign bribery: Incentives and enforcement. https://doi.org/10.2139/SSRN.1573222
   Google Scholar
• Kohler, J. C., & Baghdadi-Sabeti, G. (2011). World medicines situation 2011: Good governance for the pharmaceutical sector. https://www.thaidrugwatch.org/blog/wp-content/uploads/2012/10/WMS_ch20_wGoodGov.pdf.
   Google Scholar
• Kohler, J. C., MacKey, T. K., & Ovtcharenko, N. (2014). Why the MDGs need good governance in pharmaceutical systems to promote global health. BMC Public Health, 14(63), 1–8. https://doi.org/10.1186/1471-2458-14-63/PEER-REVIEW
   PubMedGoogle Scholar
• Kohler, J. C., & Ovtcharenko, N. (2013). Good governance for medicines initiatives: Exploring lessons learned. https://www.cmi.no/publications/file/4769-good-governance-for-medicines-initiatives.pdf.
   Google Scholar
• Legal Library. (n.d.). UNODC. Retrieved June 5, 2023, from https://track.unodc.org/track/trackview/search.html#!/search.
   Google Scholar
• Lessig, L. (2013). “Institutional corruption” defined. Journal of Law, Medicine & Ethics, 41(3), 553–555. https://doi.org/10.1111/jlme.12063
   PubMed Web of Science ®Google Scholar
• Mackey, T. K., Kohler, J. C., Savedoff, W. D., Vogl, F., Lewis, M., Sale, J., Michaud, J., & Vian, T. (2016). The disease of corruption: Views on how to fight corruption to advance 21st century global health goals. BMC Medicine, 14(149), 1–16. https://doi.org/10.1186/S12916-016-0696-1/FIGURES/10
   PubMedGoogle Scholar
• MacKey, T. K., & Liang, B. A. (2012). Combating healthcare corruption and fraud with improved global health governance. BMC International Health and Human Rights, 12(23), 1–7. https://doi.org/10.1186/1472-698X-12-23/TABLES/1
   PubMedGoogle Scholar
• Martin, J., & Ollier, L. (2012). Evaluation of the Good Governance for Medicines Programme (2004-2012). https://cdn.who.int/media/docs/default-source/evaluation-office/2012_e_goodgovernancemedicines.pdf?sfvrsn = c128fecd_5.
   Google Scholar
• Martin, J., & Schurmann, M. (2016). The medicines transparency alliance: Programmatic Review of MeTA Phase II. https://apps.who.int/iris/bitstream/handle/10665/246256/9789241565387-eng.pdf.
   Google Scholar
• Mungui-Pippidi, A., & Kossow, N. (2016). Rethinking the way we do anti-corruption. NATO Review. https://www.nato.int/docu/review/articles/2016/12/08/rethinking-the-way-we-do-anti-corruption/index.html.
   Google Scholar
• Paschke, A., Dimancesco, D., Vian, T., Kohler, J. C., & Forte, G. (2018). Increasing transparency and accountability in national pharmaceutical systems. Bulletin of the World Health Organization, 96(11), 782. https://doi.org/10.2471/BLT.17.206516
   PubMed Web of Science ®Google Scholar
• Publications Office of the European Union. (2013). Study on corruption in the healthcare sector. https://doi.org/10.2837/58154
   Google Scholar
• Rodwin, M. A. (2013). Institutional corruption and the pharmaceutical policy. Journal of Law, Medicine & Ethics, 41(3), 544–552. https://doi.org/10.1111/jlme.12062
   PubMed Web of Science ®Google Scholar
• Rose, C. (Ed.). (2015). The limitations of the United Nations convention against corruption. In International anti-corruption norms: Their creation and influence on domestic legal systems (pp. 97–132). Oxford University Press. https://doi.org/10.1093/ACPROF:OSO/9780198737216.003.0004
   Google Scholar
• The Global Action Plan for Healthy Lives and Well-being for All. (n.d). Retrieved August 7, 2023, from https://www.who.int/initiatives/sdg3-global-action-plan.
   Google Scholar
• The World Bank. (2022, August 12). Wolfensohn cancer of corruption speech. https://www.worldbank.org/en/news/video/2022/08/12/wolfensohn-cancer-of-corruption.
   Google Scholar
• Transparency International. (n.d.). What is corruption? Retrieved June 5, 2023, from https://www.transparency.org/en/what-is-corruption.
   Google Scholar
• Trivunovic, M., Taxell, N., Johnsøn, J., De, R., & Biason, C. (2013). U4 ISSUE The role of civil society in the UNCAC review process moving beyond compliance? www.U4.no.
   Google Scholar
• U4 Brief. (2007). The United Nations Convention against corruption: A primer for development practitioners. https://www.cmi.no/publications/file/2750-the-united-nations-convention-against-corruption.pdf.
   Google Scholar
• UHC2030: Our Mission. (n.d). Retrieved August 7, 2023, from https://www.uhc2030.org/about-us/about-us/.
   Google Scholar
• United Nations. (2003, October 31). Secretary-General Lauds Adoption by General Assembly of United Nations Convention against corruption. UN Press Release SG/SM/8977, GA/10200, SOC/CP/271. https://press.un.org/en/2003/sgsm8977.doc.htm.
   Google Scholar
• United Nations Convention Against Corruption. (2004). United Nations Office on Drugs and Crime. https://www.unodc.org/documents/treaties/UNCAC/Publications/Convention/08-50026_E.pdf.
   Google Scholar
• United Nations Office on Drugs and Crime. (2021, November 18). UNCAC signature and ratification status. https://www.unodc.org/unodc/en/corruption/ratification-status.html.
   Google Scholar
• UNODC. (2011). Mechanism for the review of implementation of the United Nations Convention against Corruption. https://www.unodc.org/documents/treaties/UNCAC/Publications/ReviewMechanism-BasicDocuments/Mechanism_for_the_Review_of_Implementation_-_Basic_Documents_-_E.pdf.
   Google Scholar
• UNODC. (n.d.). Implementation review mechanism. Retrieved February 10, 2024, from https://www.unodc.org/unodc/en/corruption/implementation-review-mechanism.html.
   Google Scholar
• Vian, T., & Kohler, J. C. (2016). Medicines transparency alliance (MeTA): Pathways to transparency, accountability and access. https://tspace.library.utoronto.ca/bitstream/1807/107941/1/6. MeTA- Pathways to Transparency%2C Accountability%2C and Access- Cross-Case Analysis..pdf.
   Google Scholar
• Vlassis, D. (n.d.). The United Nations convention against corruption: Origins and negotiation process. Resource Material Series No. 66. Retrieved June 5, 2023, from https://unafei.or.jp/publications/pdf/RS_No66/No66_16VE_Vlassis2.pdf.
   Google Scholar
• Webb, P. (2005). The United Nations convention against corruption. Journal of International Economic Law, 8(1), 191–229. https://doi.org/10.1093/jielaw/jgi009
   Web of Science ®Google Scholar
• Weilert, A. K. (2016). United Nations convention against corruption (UNCAC) – after ten years of being in force. Max Planck Yearbook of United Nations Law Online, 19(1), 216–240. https://doi.org/10.1163/18757413-00190008
   Google Scholar